MARKET

ATNX

ATNX

Athenex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.41
+0.54
+4.97%
Closed 16:14 06/01 EDT
OPEN
10.90
PREV CLOSE
10.87
HIGH
11.64
LOW
10.81
VOLUME
563.53K
TURNOVER
--
52 WEEK HIGH
21.11
52 WEEK LOW
5.63
MARKET CAP
931.35M
P/E (TTM)
-8.1349
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATNX stock price target is 27.75 with a high estimate of 38.00 and a low estimate of 15.25.

EPS

ATNX News

More
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
GlobeNewswire · 3d ago
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 4d ago
Edited Transcript of ATNX earnings conference call or presentation 7-May-20 12:00pm GMT
Q1 2020 Athenex Inc Earnings Call
Thomson Reuters StreetEvents · 5d ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
GlobeNewswire · 5d ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
ACCESSWIRE · 05/25 20:45
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Benzinga · 05/24 18:40
Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference
GlobeNewswire · 05/19 14:05
All You Need to Know About Athenex (ATNX) Rating Upgrade to Strong Buy
Zacks · 05/12 17:00

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About ATNX

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
More

Webull offers kinds of Athenex Inc stock information, including NASDAQ:ATNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNX stock news, and many more online research tools to help you make informed decisions.